What is the prevalence of Hyperparathyroidism?

Hyperparathyroidism is a condition characterized by the overproduction of parathyroid hormone, with primary hyperparathyroidism being the most common form, affecting approximately 1 in 500 to 1 in 1,000 adults in Western populations. While prevalence estimates vary, true figures are likely higher due to asymptomatic cases that remain undiagnosed; current data suggests a significant gender disparity, with women being affected two to three times more frequently than men.

What is the estimated prevalence and incidence of Hyperparathyroidism?

In clinical practice, the prevalence of Hyperparathyroidism is highly dependent on the subtype. Primary Hyperparathyroidism is the most frequently diagnosed form, with an estimated prevalence of roughly 1 to 4 per 1,000 individuals in the general population. The incidence of new cases is estimated at approximately 20 to 30 per 100,000 person-years. Because many patients with Hyperparathyroidism remain asymptomatic for years, these statistics likely underestimate the true burden of the disease. In the DiseaseMaps.org community, 154 individuals have shared their experiences, offering a unique, patient-centered perspective on living with this diagnosis that often complements clinical data.

How do age, gender, and geography influence Hyperparathyroidism?

Hyperparathyroidism exhibits distinct demographic patterns. While it can occur at any age, the incidence of primary Hyperparathyroidism increases significantly with age, typically peaking in individuals between 50 and 70 years old. Regarding gender, females are disproportionately affected, with women being two to three times more likely to develop the condition than men, especially following menopause. There is limited evidence of significant ethnic variation, though some studies suggest higher rates in specific populations, likely influenced by variations in vitamin D levels and genetic predispositions. Pediatric cases of Hyperparathyroidism are rare and often associated with genetic syndromes, such as Multiple Endocrine Neoplasia (MEN) types 1 and 2A.

What challenges exist in measuring the prevalence of Hyperparathyroidism?

Accurate epidemiological data for Hyperparathyroidism is difficult to capture for several critical reasons:

• Asymptomatic presentation: Many patients possess mild biochemical abnormalities without overt clinical symptoms, leading to under-testing.


• Diagnostic variability: Criteria for diagnosis have evolved over time, causing discrepancies in historical versus modern reporting.


• Incidental discovery: A significant portion of cases are identified only through routine blood panels (calcium and PTH testing) rather than through symptom-based clinical investigation.


• Misdiagnosis: Subtle symptoms—such as fatigue, bone pain, or cognitive "brain fog"—are often attributed to aging or other comorbidities, delaying the diagnosis of Hyperparathyroidism.

Is Hyperparathyroidism considered a rare disease?

While primary Hyperparathyroidism is relatively common in older adults, other forms, such as secondary or tertiary Hyperparathyroidism (often secondary to chronic kidney disease or vitamin D deficiency), have different epidemiological profiles. The classification of Hyperparathyroidism as "rare" is generally reserved for specific genetic variants or parathyroid carcinoma. Because the condition is so frequently encountered in primary care and endocrinology settings, it is often treated as a common endocrine disorder rather than an ultra-rare disease, despite the significant impact it has on the quality of life for those living with it.

Next steps

• Consult an endocrinologist to interpret your serum calcium and parathyroid hormone (PTH) levels.


• Discuss with your physician whether your symptoms warrant imaging studies, such as a sestamibi scan or neck ultrasound.


• Join the 154 members on DiseaseMaps.org to share your journey and learn from others managing their endocrine health.


• If you have a strong family history of endocrine tumors, ask your doctor about a referral to a genetic counselor.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of a qualified physician with any questions regarding a medical condition.

References

• National Institutes of Health (NIH) Genetic and Rare Diseases Information Center (GARD).


• Orphanet: Portal for rare diseases and orphan drugs.


• OMIM (Online Mendelian Inheritance in Man): Database of human genes and genetic disorders.


• The Journal of Clinical Endocrinology & Metabolism: Data on primary hyperparathyroidism prevalence.